Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2021

Open Access 01-12-2021 | Research article

The association between homocysteine levels and cardiovascular disease risk among middle-aged and elderly adults in Taiwan

Authors: Chin-Chuan Shih, Yu-Lin Shih, Jau-Yuan Chen

Published in: BMC Cardiovascular Disorders | Issue 1/2021

Login to get access

Abstract

Background

Our study aimed to determine the association between homocysteine levels and cardiovascular disease (CVD) risk in middle-aged and elderly adults in a community in northern Taiwan.

Methods

Participants in our study included adults aged 50 to 85 years old during community health examinations in 2019. A total of 396 people were enrolled, the ethnicity of all participants is Chinese. We divided participants according to tertiles of ln[homocysteine] level (low, middle and high groups). The CVD risk was calculated by the Framingham cardiovascular risk score (FRS). An FRS ≥ 20% indicated high CVD risk. Pearson correlation coefficients were calculated between homocysteine level and other cardio-metabolic risk factors while adjusting for age. Multivariate logistic regression analysis was used to determine the association of high and middle ln[homocysteine] groups with high CVD risk after adjusting age, sex, uric acid, creatinine, and body mass index (BMI). The Youden index and receiver operating characteristic (ROC) curves were performed to determine the optimized cut-off value.

Results

There were 396 people enrolled for analysis; 41.4% of participants were male, and the average age was 64.79 (± 8.76). In our study, we showed a positive correlation of homocysteine with FRS. In the logistic regression models, higher ln[homocysteine] levels was associated with higher CVD risk with a odds ratio (OR) of 2.499 and 95% confidence interval (CI) of 1.214 to 5.142 in the high homocysteine level group compared with the low homocysteine group after adjusting for traditional CVD risk factors. The area under the ROC curve was 0.667, and a ln[homocysteine] cut-off value of 2.495 µmol/L was determined.

Conclusions

Middle-aged and elderly people with increased homocysteine levels were associated with higher FRSs in this Taiwan community. Furthermore, homocysteine was an independent risk factor for high CVD risk in this study.
Literature
1.
go back to reference Centers for Disease Control and Prevention. Leading causes of death and numbers of deaths, by sex, race, and Hispanic origin: United States, 1980 and 2014. CDC;2015. Centers for Disease Control and Prevention. Leading causes of death and numbers of deaths, by sex, race, and Hispanic origin: United States, 1980 and 2014. CDC;2015.
2.
go back to reference World Health Organization. World Health Organization: deaths by cause, age and sex, by world bank income group, 2000–2015. WHO: Geneva 2018. World Health Organization. World Health Organization: deaths by cause, age and sex, by world bank income group, 2000–2015. WHO: Geneva 2018.
3.
go back to reference Pagidipati NJ, Gaziano TA. Estimating deaths from cardiovascular disease: a review of global methodologies of mortality measurement. Circulation. 2013;2:12. Pagidipati NJ, Gaziano TA. Estimating deaths from cardiovascular disease: a review of global methodologies of mortality measurement. Circulation. 2013;2:12.
4.
go back to reference Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet. 2013;9:29. Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet. 2013;9:29.
5.
go back to reference Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutrit. 2006;83(2):456S-460S.CrossRef Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutrit. 2006;83(2):456S-460S.CrossRef
6.
go back to reference Nilsson J. CRP—marker or maker of cardiovascular disease. Arterioscler Thromb Vasc Biol. 2005;25:1527–8.CrossRef Nilsson J. CRP—marker or maker of cardiovascular disease. Arterioscler Thromb Vasc Biol. 2005;25:1527–8.CrossRef
7.
go back to reference Yayan J. Erythrocyte sedimentation rate as a marker for coronary heart disease. Vasc Health Risk Manag. 2012;8:219–23.CrossRef Yayan J. Erythrocyte sedimentation rate as a marker for coronary heart disease. Vasc Health Risk Manag. 2012;8:219–23.CrossRef
8.
go back to reference Chrysant SG, Chrysant GS. The current status of homocysteine as a risk factor for cardiovascular disease: a mini review. Exp Rev Cardiovasc Therapy. 2018;16(8):559–65.CrossRef Chrysant SG, Chrysant GS. The current status of homocysteine as a risk factor for cardiovascular disease: a mini review. Exp Rev Cardiovasc Therapy. 2018;16(8):559–65.CrossRef
9.
go back to reference Balint B, Jepchumba VK, Guéant JL, Guéant-Rodriguez RM. Mechanisms of homocysteine-induced damage to the endothelial, medial and adventitial layers of the arterial wall. Biochimie. 2020;173:100–6.CrossRef Balint B, Jepchumba VK, Guéant JL, Guéant-Rodriguez RM. Mechanisms of homocysteine-induced damage to the endothelial, medial and adventitial layers of the arterial wall. Biochimie. 2020;173:100–6.CrossRef
10.
go back to reference Finch M, Joseph J. Homocysteine, cardiovascular inflammation, and myocardial remodeling. Cardiovasc Haematol Disorders Drug Targets. 2010;10(4):241–5.CrossRef Finch M, Joseph J. Homocysteine, cardiovascular inflammation, and myocardial remodeling. Cardiovasc Haematol Disorders Drug Targets. 2010;10(4):241–5.CrossRef
11.
go back to reference nkle Brachial Index Collaboration. Ankle brachial index combined with framingham risk score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300(2):197.CrossRef nkle Brachial Index Collaboration. Ankle brachial index combined with framingham risk score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300(2):197.CrossRef
12.
go back to reference Lin BY, Li P, Wu XD, Li H, Zeng ZY. The relationship between homocysteine, blood pressure variability, and left ventricular hypertrophy in patients with essential hypertension: an observational study. Advances in therapy. 2020;37(1):381–9.CrossRef Lin BY, Li P, Wu XD, Li H, Zeng ZY. The relationship between homocysteine, blood pressure variability, and left ventricular hypertrophy in patients with essential hypertension: an observational study. Advances in therapy. 2020;37(1):381–9.CrossRef
13.
go back to reference Awasthi M, Omoike OE, Paul TK, Ridner SL, Mamudu HM, An association between smoking status and homocysteine levels and whether this association is modified by sex hormones and cholesterol (2019) Awasthi M, Omoike OE, Paul TK, Ridner SL, Mamudu HM, An association between smoking status and homocysteine levels and whether this association is modified by sex hormones and cholesterol (2019)
14.
go back to reference Weng H, Li Y, Fan F, Yang H, Zhou G, Sun P, Li J. The association between total homocysteine and blood pressure in two independent Chinese populations. J Hum Hyperten. 2020;34(9):657–65.CrossRef Weng H, Li Y, Fan F, Yang H, Zhou G, Sun P, Li J. The association between total homocysteine and blood pressure in two independent Chinese populations. J Hum Hyperten. 2020;34(9):657–65.CrossRef
15.
go back to reference Momin M, Jia J, Fan F, Li J, Dou J, Chen D, Zhang Y. Relationship between plasma homocysteine level and lipid profiles in a community-based Chinese population. Lip Health Disease. 2017;16(1):1–7.CrossRef Momin M, Jia J, Fan F, Li J, Dou J, Chen D, Zhang Y. Relationship between plasma homocysteine level and lipid profiles in a community-based Chinese population. Lip Health Disease. 2017;16(1):1–7.CrossRef
16.
go back to reference Lloyd-Jones DM, Wilson PW, Larson MG, Beiser A, Leip EP, D’Agostino RB, Levy D. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol. 2004;94(1):20–4.CrossRef Lloyd-Jones DM, Wilson PW, Larson MG, Beiser A, Leip EP, D’Agostino RB, Levy D. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol. 2004;94(1):20–4.CrossRef
17.
go back to reference Chrysant SG, Chrysant GS. The current status of homocysteine as a risk factor for cardiovascular disease: a mini review. Exp Rev Cardiovas Therapy. 2018;16(8):559–65.CrossRef Chrysant SG, Chrysant GS. The current status of homocysteine as a risk factor for cardiovascular disease: a mini review. Exp Rev Cardiovas Therapy. 2018;16(8):559–65.CrossRef
18.
go back to reference Castro R, Rivera I, Blom HJ, Jakobs C, De Almeida IT. Homocysteine metabolism, hyperhomocysteinaemia and vascular disease: an overview. J Inherited Metab Dis. 2006;29(1):3–20.CrossRef Castro R, Rivera I, Blom HJ, Jakobs C, De Almeida IT. Homocysteine metabolism, hyperhomocysteinaemia and vascular disease: an overview. J Inherited Metab Dis. 2006;29(1):3–20.CrossRef
19.
go back to reference Menon V, Sarnak MJ, Greene T, Wang X, Pereira AA, Beck GJ, Shlipak MG. Relationship between homocysteine and mortality in chronic kidney disease. Circulation. 2006;113(12):1572–7.CrossRef Menon V, Sarnak MJ, Greene T, Wang X, Pereira AA, Beck GJ, Shlipak MG. Relationship between homocysteine and mortality in chronic kidney disease. Circulation. 2006;113(12):1572–7.CrossRef
20.
go back to reference Obeid R. The metabolic burden of methyl donor deficiency with focus on the betaine homocysteine methyltransferase pathway. Nutrients. 2013;5(9):3481–95.CrossRef Obeid R. The metabolic burden of methyl donor deficiency with focus on the betaine homocysteine methyltransferase pathway. Nutrients. 2013;5(9):3481–95.CrossRef
21.
go back to reference Bukharaeva E, Shakirzyanova A, Khuzakhmetova V, Sitdikova G, Giniatullin R. Homocysteine aggravates ROS-induced depression of transmitter release from motor nerve terminals: potential mechanism of peripheral impairment in motor neuron diseases associated with hyperhomocysteinemia. Front Cellular Neurosci. 2015;9:391.CrossRef Bukharaeva E, Shakirzyanova A, Khuzakhmetova V, Sitdikova G, Giniatullin R. Homocysteine aggravates ROS-induced depression of transmitter release from motor nerve terminals: potential mechanism of peripheral impairment in motor neuron diseases associated with hyperhomocysteinemia. Front Cellular Neurosci. 2015;9:391.CrossRef
22.
go back to reference Ke XD, Foucault-Bertaud A, Genovesio C, Dignat-George F, Lamy E, Charpiot P. Homocysteine modulates the proteolytic potential of human arterial smooth muscle cells through a reactive oxygen species dependant mechanism. Mol Cellular Biochem. 2010;335(1):203–10.CrossRef Ke XD, Foucault-Bertaud A, Genovesio C, Dignat-George F, Lamy E, Charpiot P. Homocysteine modulates the proteolytic potential of human arterial smooth muscle cells through a reactive oxygen species dependant mechanism. Mol Cellular Biochem. 2010;335(1):203–10.CrossRef
23.
go back to reference Durand P, Prost M, Loreau N, Lussier-Cacan S, Blache D. Impaired homocysteine metabolism and atherothrombotic disease. Lab Investig. 2001;81(5):645–72.CrossRef Durand P, Prost M, Loreau N, Lussier-Cacan S, Blache D. Impaired homocysteine metabolism and atherothrombotic disease. Lab Investig. 2001;81(5):645–72.CrossRef
24.
go back to reference Sreckovic B, Sreckovic VD, Soldatovic I, Colak E, Sumarac-Dumanovic M, Janeski H, Mrdovic I. Homocysteine is a marker for metabolic syndrome and atherosclerosis. Diabetes Metab Syndrome Clin Res Rev. 2017;11(3):179–82.CrossRef Sreckovic B, Sreckovic VD, Soldatovic I, Colak E, Sumarac-Dumanovic M, Janeski H, Mrdovic I. Homocysteine is a marker for metabolic syndrome and atherosclerosis. Diabetes Metab Syndrome Clin Res Rev. 2017;11(3):179–82.CrossRef
25.
go back to reference Lehotský J, Tothová B, Kovalská M, Dobrota D, Beňová A, Kalenská D, Kaplán P. Role of homocysteine in the ischemic stroke and development of ischemic tolerance. Front Neurosci. 2016;10:538.CrossRef Lehotský J, Tothová B, Kovalská M, Dobrota D, Beňová A, Kalenská D, Kaplán P. Role of homocysteine in the ischemic stroke and development of ischemic tolerance. Front Neurosci. 2016;10:538.CrossRef
26.
go back to reference Schaffer A, Verdoia M, Barbieri L, Aprami TM, Suryapranata H, Marino P, Luca GD. High-density lipoproteins and coronary artery disease: a single-center cohort study. Angiology. 2014;65(8):696–702.CrossRef Schaffer A, Verdoia M, Barbieri L, Aprami TM, Suryapranata H, Marino P, Luca GD. High-density lipoproteins and coronary artery disease: a single-center cohort study. Angiology. 2014;65(8):696–702.CrossRef
27.
go back to reference Andras A, Stansby G, Hansrani M. Homocysteine lowering interventions for peripheral arterial disease and bypass grafts. Cochrane Database Syst Rev, 2013;7 Andras A, Stansby G, Hansrani M. Homocysteine lowering interventions for peripheral arterial disease and bypass grafts. Cochrane Database Syst Rev, 2013;7
28.
go back to reference Krishna SM, Dear A, Craig JM, Norman PE, Golledge J. The potential role of homocysteine mediated DNA methylation and associated epigenetic changes in abdominal aortic aneurysm formation. Atherosclerosis. 2013;228(2):295–305.CrossRef Krishna SM, Dear A, Craig JM, Norman PE, Golledge J. The potential role of homocysteine mediated DNA methylation and associated epigenetic changes in abdominal aortic aneurysm formation. Atherosclerosis. 2013;228(2):295–305.CrossRef
Metadata
Title
The association between homocysteine levels and cardiovascular disease risk among middle-aged and elderly adults in Taiwan
Authors
Chin-Chuan Shih
Yu-Lin Shih
Jau-Yuan Chen
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2021
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-021-02000-x

Other articles of this Issue 1/2021

BMC Cardiovascular Disorders 1/2021 Go to the issue